| Patents for A61P 37 - Drugs for immunological or allergic disorders (117,141) |
|---|
| 02/27/2001 | US6194585 Process for preparing 5-lipoxygenase inhibitors |
| 02/27/2001 | US6194561 Oligonucleotide probes of defined nucleotide sequences which are complementary to second exon of class ii hla beta chain gene; diagnosis of susceptibility to insulin-dependent diabetes mellitus and pemphigus vulgaris; antidiabetic agents |
| 02/27/2001 | US6194560 Synthetic escherichia coli gene which encodes lt-b; the dna sequence is optimized for plant codon usage; feeds; foods |
| 02/27/2001 | US6194458 1-(2-methoxyphenyl)-1-oxo-2-aza-(s)-4-i-butyl-4-phenylbutane, for example; treating various conditions including transplantation rejection of organs or tissues in a patient; immunosuppressant compositions |
| 02/27/2001 | US6194451 Prevent release tumor necrosis factor; antiinflammatory agents |
| 02/27/2001 | US6194448 N, N-disubstituted amides that inhibit the binding of integrins to their receptors |
| 02/27/2001 | US6194431 Methods and compositions using terfenadine metabolites in combination with leukotriene inhibitors |
| 02/27/2001 | US6194425 Viricides, antitumor agents |
| 02/27/2001 | US6194401 Pharmaceutical compositions containing cyclosporine and a carrier comprising at least an ester of α-glycerophosphoric acid |
| 02/27/2001 | US6194392 Administering to a patient suffering from swelling associated with brain tumours involving tissue of the group consisting of underperfused tissue and pathological tissue an antiswelling agent and a hyaluronic acid to aid penetration |
| 02/27/2001 | US6194388 Immunomodulatory oligonucleotides |
| 02/27/2001 | US6194207 Methods for the selective expansion of lymphocytes by in vitro cultivation |
| 02/27/2001 | US6194186 Human protein kinase and kinase inhibitors |
| 02/27/2001 | US6194020 Conserving procyanidins(catechins); candy |
| 02/27/2001 | US6193979 Compositions comprising complement receptor type 1 molecules having carbohydrate structures that are selectin ligands |
| 02/27/2001 | US6193970 Potentiating local inflammatory or immune response to administration of tumor antigen in mammalian subject by administering tumor antigen in form of tumor cells, or subcellular antigenic material and cytokine or cytokines |
| 02/27/2001 | US6193965 Administering therapeutically effective amount of reagent which modulates kinase activity for treating cell proliferative disorder associated with c-jun n-terminal kinase disorder, |
| 02/27/2001 | US6193957 For prophylaxis and therapy of airway hyperresponsiveness or inflammatory reactions, e.g., asthma, allergic rhinitis, allergic dermatitis, allergic conjunctivitis, inflammatory bowel disease or rheumatoid arthritis |
| 02/27/2001 | CA2190952C Use of a naphthalenesulfonic acid compound for inhibiting retroviral infection |
| 02/27/2001 | CA2110582C Modified sialyl lewis a compounds |
| 02/22/2001 | WO2001012812A2 Baff receptor (bcma), an immunoregulatory agent |
| 02/22/2001 | WO2001012804A2 MODULATION OF OLIGONUCLEOTIDE CpG-MEDIATED IMMUNE STIMULATION BY POSITIONAL MODIFICATION OF NUCLEOSIDES |
| 02/22/2001 | WO2001012790A2 Isomerase proteins |
| 02/22/2001 | WO2001012776A2 18 human secreted proteins |
| 02/22/2001 | WO2001012775A2 25 human secreted proteins |
| 02/22/2001 | WO2001012674A1 Ovarian cancer cell and myeloma cell surface glycoproteins, antibodies thereto, and uses thereof |
| 02/22/2001 | WO2001012673A1 Pgpcr-3 polypeptides and dna sequences thereof |
| 02/22/2001 | WO2001012672A2 Cytokine receptor common gamma chain like |
| 02/22/2001 | WO2001012671A1 Human tumor necrosis factor receptor tr16 |
| 02/22/2001 | WO2001012670A1 Tgf-beta receptor polynucleotides, polypeptides, and antibodies |
| 02/22/2001 | WO2001012665A2 Helical cytokine zalpha48 |
| 02/22/2001 | WO2001012662A2 Membrane associated proteins |
| 02/22/2001 | WO2001012633A1 Water soluble sdz-rad esters |
| 02/22/2001 | WO2001012621A1 INHIBITORS OF c-JUN N-TERMINAL KINASES (JNK) AND OTHER PROTEIN KINASES |
| 02/22/2001 | WO2001012618A1 Dihydroaminobenzo[b]- and [c]furans as retinoid-like agents |
| 02/22/2001 | WO2001012611A1 Pyrimidine-2,4,6-trione metalloproteinase inhibitors |
| 02/22/2001 | WO2001012608A1 Quinoline compounds and process for producing the same |
| 02/22/2001 | WO2001012607A2 Pharmaceutical compositions comprising 4-quinolones for treating cancers |
| 02/22/2001 | WO2001012606A2 Tetrahydroquinoline derivatives having retinoid-like biological activity |
| 02/22/2001 | WO2001012598A2 METHODS OF INHIBITING BINDING OF β-SHEET FIBRIL TO RAGE AND CONSEQUENCES THEREOF |
| 02/22/2001 | WO2001012592A2 Hydroxamic acid compounds useful as matrix metalloproteinase inhibitors |
| 02/22/2001 | WO2001012588A1 Salicylamide derivatives |
| 02/22/2001 | WO2001012584A2 Pharmaceutical compounds |
| 02/22/2001 | WO2001012264A2 Topical azathioprine for the treatment of oral autoimmune diseases |
| 02/22/2001 | WO2001012229A1 Pharmaceutical compositions for oral and topical administration |
| 02/22/2001 | WO2001012223A2 Methods of modulating an immune response using immunostimulatory sequences and compositions for use therein |
| 02/22/2001 | WO2001012222A1 Immunological tolerance-induction agent |
| 02/22/2001 | WO2001012216A1 Heat shock fusion-based vaccine system |
| 02/22/2001 | WO2001012212A1 Inhibitors of the lectin complement pathway (lcp) and their use |
| 02/22/2001 | WO2001012197A1 Pyridomorphinans, thienomoprhinans and use thereof |
| 02/22/2001 | WO2001012196A1 Pyridomorphinans and use thereof |
| 02/22/2001 | WO2001012193A1 Pharmaceutical agent comprising a benzamide derivative as active ingredient |
| 02/22/2001 | WO2001012189A1 3(5)-amino-pyrazole derivatives, process for their preparation and their use as antitumor agents |
| 02/22/2001 | WO2001012186A1 Cell adhesion inhibitors |
| 02/22/2001 | WO2001012175A1 Uses compositions for treating or preventing sleep disturbances using very low doses of cyclobenzaprine |
| 02/22/2001 | WO2001012155A1 Compositions and methods for enhanced absorption of hydrophilic therapeutic agents |
| 02/22/2001 | WO2001011967A1 Novel hypoxanthine and thiohypoxanthine compounds |
| 02/22/2001 | WO2000078941A3 Methods and products for manipulating uncoupling protein expression |
| 02/22/2001 | WO2000077179A3 Human poly(adp-ribose) polymerase 2 materials and methods |
| 02/22/2001 | WO2000071538A3 1-trifluoromethyl-4-hydroxy-7-piperidinyl-aminomethylchroman derivatives |
| 02/22/2001 | WO2000064936A3 PEPTIDE HOMODIMERS AND PEPTIDE HETERODIMERS, DERIVED FROM INTERFERON α2 |
| 02/22/2001 | WO2000062788A3 Treatment of hypersensitivity reaction disorders |
| 02/22/2001 | WO2000058314A3 Sulfamate containing macrocyclic immunomodulators |
| 02/22/2001 | WO2000055633A3 Methods of screening for colorectal cancer modulators |
| 02/22/2001 | WO2000055126A3 N-cyanomethylamides as protease inhibitors |
| 02/22/2001 | WO2000050073A3 Caulobacter lps immunoadjuvant |
| 02/22/2001 | WO2000036107A3 Compositions and methods for therapy and diagnosis of ovarian cancer |
| 02/22/2001 | DE19939463A1 Tryptase inhibitors useful e.g. for treating inflammatory or allergic disease, arteriosclerosis or neoplasia, comprising new or known 2-phenethyl-benzimidazole-5-carboxamides |
| 02/22/2001 | CA2784789A1 Modulation of oligonucleotide cpg-mediated immune stimulation by positional modification of nucleosides |
| 02/22/2001 | CA2698353A1 Pharmaceutical compounds |
| 02/22/2001 | CA2452118A1 Pharmaceutical compositions for oral and topical administration |
| 02/22/2001 | CA2391319A1 Water soluble sdz-rad esters |
| 02/22/2001 | CA2385475A1 18 human secreted proteins |
| 02/22/2001 | CA2385431A1 Tgf-beta receptor polynucleotides, polypeptides, and antibodies |
| 02/22/2001 | CA2383922A1 Cytokine receptor common gamma chain like |
| 02/22/2001 | CA2383691A1 Human tumor necrosis factor receptor tr16 |
| 02/22/2001 | CA2383268A1 Pyrazoloanthrone and derivatives thereof as jnk inhibitors and their compositions |
| 02/22/2001 | CA2383154A1 Baff receptor (bcma), an immunoregulatory agent |
| 02/22/2001 | CA2382749A1 Amines substituted with a dihydro-isobenzofuranyl group, an aryl or heteroaryl group and an alkyl group, having retinoid-like biological activity |
| 02/22/2001 | CA2382148A1 25 human secreted proteins |
| 02/22/2001 | CA2382095A1 Methods of inhibiting binding of .beta.-sheet fibril to rage and consequences thereof |
| 02/22/2001 | CA2382019A1 Isomerase proteins |
| 02/22/2001 | CA2382015A1 Membrane associated proteins |
| 02/22/2001 | CA2381993A1 Modulation of oligonucleotide cpg-mediated immune stimulation by positional modification of nucleosides |
| 02/22/2001 | CA2381979A1 Pgpcr-3 polypeptides and dna sequences thereof |
| 02/22/2001 | CA2381971A1 Amines substituted with a tetrahydroquinolinyl group, an aryl or heteroaryl group and an alkyl group, having retinoid-like biological acitity |
| 02/22/2001 | CA2381968A1 Pharmaceutical compositions comprising 4-quinolones for treating cancers |
| 02/22/2001 | CA2381794A1 Helical cytokine zalpha48 |
| 02/22/2001 | CA2381706A1 Ovarian cancer cell and myeloma cell surface glycoproteins, antibodies thereto, and uses thereof |
| 02/22/2001 | CA2381551A1 Pyrimidine-2,4,6-trione metalloproteinase inhibitors |
| 02/22/2001 | CA2381409A1 Nitric ester derivatives |
| 02/22/2001 | CA2380979A1 Inhibitors of the lectin complement pathway (lcp) and their use |
| 02/22/2001 | CA2380817A1 Cell adhesion inhibitors |
| 02/22/2001 | CA2380814A1 Pyridomorphinans, thienomorphinans and use thereof |
| 02/22/2001 | CA2380642A1 Compositions and methods for enhanced absorption of hydrophilic therapeutic agents |
| 02/22/2001 | CA2380432A1 Uses compositions for treating or preventing sleep disturbances using very low doses of cyclobenzaprine |
| 02/22/2001 | CA2379356A1 Novel hypoxanthine and thiohypoxanthine compounds |
| 02/22/2001 | CA2378332A1 Hydroxamic acid compounds useful as matrix metalloproteinase inhibitors |
| 02/21/2001 | EP1076704A1 Il-2 selective agonists and antagonists |
| 02/21/2001 | EP1076702A1 Human protease associated proteins |